Indian Patent Law Very Strong, Par with Global Stds: Maruti
These statements assume significance against the backdrop of U.S. industry, particularly the pharmaceuticals sector, and trade lobbies putting pressure on their government to place India under the Priority Foreign Country list for IPR. Under the U.S. Trade Act, a Priority Foreign Country is the worst classification given to those that deny adequate and effective protection of IPR or fair and equitable market access to US entities, relying on IPR protection.
The U.S. Trade Representative (USTR) in its Special 301 report had kept India out of the Priority list and had said that it would hold discussions with the next government in New Delhi on enforcement and protection of IP
However, the U.S. has said that they would do an 'out-of-cycle' review of India's IPR regime. The U.S. industry had raised the matter of India's rejection of patents for Bristol-Myers Squibb's Sprycel and Novartis AG's Glivec. India has always maintained that its IPR regime is fully compliant with WTO norms and it would drag the US to the global trade body if any adverse unilateral step is taken against the country in IPR-related matters.
Maruti Suzuki stock price On June 03, 2014, Maruti Suzuki India closed at 2342.85, up 16.00, or 0.69 percent. The 52-week high of the share was 2505.30 and the 52-week low was 1217.00. The company's trailing 12-month (TTM) EPS was at 92.13 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 25.43. The latest book value of the company is 707.16 per share. At current value, the price-to-book value of the company is 3.31.
READ MORE: Indians Can Invest Up To $125,000 Overseas Annually
